AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$162.70
-2.07 (-1.26%)
▼
5d:
+0.0%
30d:
+1.01%
90d:
-12.5%
HOLD
MODERATE Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Jul 27, 2026
0d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$426.12
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$264.59
38.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $162.70, which is considered fair relative to its 30-day fair value range of $158.63 to $168.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.3) compared to its historical average (26.1). Remarkably, the market is currently pricing in an annual earnings decline of 18.1% over the next few years. This pessimistic expectation contrasts with the company's recent 2.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a strong downtrend. The price is currently testing key support at $160.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $212.54 (+30.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a strong downtrend. The price is currently testing key support at $160.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $212.54 (+30.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$158.63 -
$168.22
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.6% below Wall St target ($212.54)
- NEUTRAL: Bottoming setup forming (51/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$158.63 -
$168.22
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$160.87
Resistance Level
$170.18
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.32
Wall Street Target
$212.54
(+30.6%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
2.5%
Profit Margin
17.0%
Valuation Discount vs History
-18.1% cheaper
PE vs Historical
14.3 vs 26.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.1%
(market-implied from PE analysis)
1-Year Target
$146.43
(-10%)
2-Year Target
$131.79
(-19%)
3-Year Target
$118.61
(-27%)
3-Yr Target (if PE normalizes)
(PE: 14→26)
$216.15
(+33%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 13.0%)
$331.58
(+104%)
Base:
(SPY PE: 14.3, Growth: 13.0%)
$234.75
(+44%)
Bear:
(PE: 12.2, Growth: 13.0%)
$199.53
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 24.20 | Current EPS (TTM): $6.81
Bull Case
$302.34
(+86%)
Analyst growth 66.8%, PE expands to 26.6
Base Case
$274.86
(+69%)
Market implied 66.8%, PE stable at 24.2
Bear Case
$112.04
(-31%)
Severe decline -20.0%, PE contracts to 20.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.3 to 26.1
Stabilization Target:
$296.50
(+82.2%)
PE Expansion Potential:
+82.2%
Share & Embed Analysis
Last updated: September 05, 2026 7:08 AM ET
Data refreshes hourly during market hours. Next update: 8:08 AM
Data refreshes hourly during market hours. Next update: 8:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 43 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 39 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 51 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 51 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 47 HOLD |
